VBI Vaccines (VBIV) & Grifols SA, Barcelona (GRFS) Head-To-Head Analysis

VBI Vaccines (NASDAQ: VBIV) and Grifols SA, Barcelona (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares VBI Vaccines and Grifols SA, Barcelona’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -4,463.06% -49.17% -37.55%
Grifols SA, Barcelona 13.16% 18.08% 6.22%

Valuation & Earnings

This table compares VBI Vaccines and Grifols SA, Barcelona’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VBI Vaccines $550,000.00 440.87 -$23.20 million ($0.73) -5.21
Grifols SA, Barcelona $4.48 billion 3.47 $603.60 million N/A N/A

Grifols SA, Barcelona has higher revenue and earnings than VBI Vaccines.

Analyst Ratings

This is a summary of recent ratings and target prices for VBI Vaccines and Grifols SA, Barcelona, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 3 0 3.00
Grifols SA, Barcelona 0 1 3 0 2.75

VBI Vaccines currently has a consensus price target of $10.50, indicating a potential upside of 176.32%. Given VBI Vaccines’ stronger consensus rating and higher possible upside, equities analysts plainly believe VBI Vaccines is more favorable than Grifols SA, Barcelona.

Risk and Volatility

VBI Vaccines has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, Grifols SA, Barcelona has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Dividends

Grifols SA, Barcelona pays an annual dividend of $0.28 per share and has a dividend yield of 1.2%. VBI Vaccines does not pay a dividend.

Insider and Institutional Ownership

20.9% of VBI Vaccines shares are held by institutional investors. Comparatively, 22.4% of Grifols SA, Barcelona shares are held by institutional investors. 34.1% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Grifols SA, Barcelona beats VBI Vaccines on 8 of the 13 factors compared between the two stocks.

VBI Vaccines Company Profile

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

Grifols SA, Barcelona Company Profile

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply